Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Reduces Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,533 shares of the biopharmaceutical company’s stock after selling 257 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Alnylam Pharmaceuticals were worth $361,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth $61,160,000. Strategic Financial Concepts LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $41,529,000. Eventide Asset Management LLC raised its stake in Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after buying an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after buying an additional 135,829 shares during the period. Finally, Telemark Asset Management LLC bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $27,503,000. 92.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,964 shares of company stock valued at $20,622,925. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $276.19 on Monday. The firm has a market capitalization of $35.62 billion, a P/E ratio of -105.42 and a beta of 0.35. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The business has a fifty day moving average of $252.78 and a 200 day moving average of $262.47.

Wall Street Analyst Weigh In

ALNY has been the subject of several research reports. Barclays increased their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Piper Sandler reissued an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Raymond James boosted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Scotiabank increased their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.